Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00545610 · ClinicalTrials.gov registry record
ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)
A clinical trial, sponsored by Lisata Therapeutics.
- Completed
- Registry status
- 150
- Enrollment target
NCT00545610: Completed study, sponsored by Lisata Therapeutics.
NCT00545610 is a clinical trial that has completed, run by Lisata Therapeutics. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00545610 has completed, sponsored by Lisata Therapeutics.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The purpose of this 12-month, observational, follow-up study is to collect additional data (by telephone contact) with which to assess the efficacy, safety, and effects of intramyocardial injections of adult autologous CD34+ cells on quality of life (QoL) in subjects with chronic refractory myocardial ischemia. No treatments will be administered during this study. However, the investigators and other study site personnel and the subjects will remain blinded to the treatment assignments from the core therapeutic study (# 24779) so as to provide a total of 24 months of blinded data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-06 |
What the finished NCT00545610 record still lists
NCT00545610 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00545610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00545610 about?
NCT00545610 is a clinical study titled "ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)". The purpose of this 12-month, observational, follow-up study is to collect additional data (by telephone contact) with which to assess the efficacy, safety, and effects of intramyocardial injections of adult autologous CD34+ cells on quality of life (QoL) in subjects with chronic refractory myocardi...
What is the current status of trial NCT00545610?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2007-10. Estimated completion is 2010-06.
Who is sponsoring clinical trial NCT00545610?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia